

**Novacyt S.A.**

**("Novacyt" or the "Company")**

## **Publication of Annual Report**

**Paris, France and Camberley, UK – 30 June 2020** – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company's Annual Report and Accounts ("Annual Report") for the year ended 31 December 2019 has been published and uploaded to the Company's website. The Annual Report will be posted to all shareholders that hold ordinary shares through CREST Depository Interests (CDIs) by 3 July 2020.

It is intended that the Company's Annual General Meeting ("AGM") will be held in September 2020 further details of which will be provided to shareholders in due course.

An electronic copy of the Annual Report is available on the Company's website at [www.novacyt.com](http://www.novacyt.com). Alternatively, a hard copy is available from either 13 Avenue Morane Saulnier, 78140 Vélizy-Villacoublay, France or Unit 1, Watchmoor Point, Watchmoor Road, Camberley, Surrey, GU15 3AD or will be posted to shareholders upon request from [investor.relations@novacyt.com](mailto:investor.relations@novacyt.com).

**- End -**

### **Contacts**

#### **Novacyt S.A.**

Graham Mullis, Chief Executive Officer  
Anthony Dyer, Chief Financial Officer  
+44 (0)1276 600081

#### **SP Angel Corporate Finance LLP (Nominated Adviser and Broker)**

Matthew Johnson / Charlie Bouverat (Corporate Finance)  
Vadim Alexandre / Rob Rees (Corporate Broking)  
+44 (0)20 3470 0470

#### **FTI Consulting (International)**

Victoria Foster Mitchell / Mary Whittow  
+44 (0)20 3727 1000

[victoria.fostermitchell@fticonsulting.com](mailto:victoria.fostermitchell@fticonsulting.com) / [mary.whittow@fticonsulting.com](mailto:mary.whittow@fticonsulting.com)

#### **FTI Consulting (France)**

Arnaud de Cheffontaines  
+33 (0)147 03 69 47

[arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

### **About Novacyt Group**

**The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products,**

**supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.**

**For more information please refer to the website: [www.novacyt.com](http://www.novacyt.com)**